[Endothelins: possibly a new pharmacological approach in cardiovascular diseases, kidney diseases and oncological disorders].
Only 10 years ago, the vasoconstricting peptide endothelin was discovered; it is produced by endothelial cells. Different isoforms and receptors of endothelin have been identified. The effects of endothelin-I, the most important isoform, are mainly vasoconstriction and proliferation of cells. In the last few years endothelin receptor antagonists have become available, which can delineate the clinical importance of the endothelin system. Possible indications for endothelin receptor blockers are renal disease (acute and chronic renal failure) and cardiovascular disease (heart failure; restenosis after percutaneous transluminal coronary angioplasty (PTCA); pulmonary hypertension; systemic hypertension). There is also a possible role for endothelin receptor blockers in oncology (prostatic carcinoma). Currently clinical trials are being carried out to determine the efficacy of these compounds for the above-mentioned indications.
Kroodsma
J M
JM
Academisch Ziekenhuis, afd. Nefrologie, Utrecht.
Rabelink
A J
AJ
D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000503:physiopathology*; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000096:biosynthesis / Q000502:physiology; D016232:Endothelins / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000503:physiopathology*; D017466:Receptors, Endothelin / Q000502:physiology
D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D016232:Endothelins; D017466:Receptors, Endothelin